Population-based prostate cancer (PCa) screening using prostate-specific antigen (PSA) and standard transrectal ultrasound-guided prostate biopsies in men with elevated PSA levels reduces cancer-specific mortality [1]. This evidence concerns the gene KLK3 and posterior cortical atrophy.